This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $278,224 to Sonomotion Inc. to develop a new non-invasive technology called "Break Wave Lithotripsy" to safely fragment large kidney stones up to 20 mm in size. The project aims to expand on previous successful testing of this ultrasound-based technology for 10 mm...
This $684,107 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under CFDA program 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research, supports research to determine the optimal settings for the Thulium Fiber Laser (TFL) in laser lithotripsy and assess associated thermal injury risk. The key objectives are to: 1) determine the optimal TFL settings through in-vitro studies, 2) elucidate the mechanisms of action of the...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) is supporting research to investigate the role of protein interactions in the formation of calcium oxalate kidney stones. The total award amount is $851,542 over the period from Aug 22, 2024 to Jun 30, 2028. The research aims to: 1) Test a range of protein/polymer compositions to understand how they...
This $675,480 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to develop a novel therapeutic compound for treating chronic kidney disease (CKD). The awardee, Fibrotherapeutics Inc., is conducting preclinical studies to evaluate the efficacy, safety, and therapeutic index of a modified, water-soluble, orally-active peptide derived...
This $1,543,110 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) to New York University School of Medicine aims to better understand how the gut microbiome and other host factors determine urine oxalate levels. The research has three key objectives: Investigate the role of the "oxalobiome" (microbes that degrade oxalate) in determining urine oxalate excretion, and whether it differs between kidney stone formers and non-stone...
The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $702,754 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Mayo Clinic to develop artificial intelligence-based methods for characterizing kidney macrostructure from pre- and post-nephrectomy computed tomography (CT) images. The goal is to evaluate automated imaging biomarkers as prognostic tools for predicting progressive chronic kidney disease in patients...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $436,277 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Delaware. The grant titled "NEPHROGENESIS ON A CHIP: AN SIMPLE MODULAR PLATFORM TO SPATIALLY PATTERN EXTRACELLULAR MATRIX, STROMAL CELLS, AND SOLUBLE FACTORS" aims to develop an easy-to-use 3D in vitro model of the developing nephron that allows spatial patterning...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is funding research to develop a deep learning model that can diagnose urinary tract obstruction in children with antenatal hydronephrosis more accurately than current clinical standards. The $155,011 award, with a project period from March 15, 2025 to January 31, 2030, aims to create a multimodal...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to leverage a unique dog model to investigate the role of the protein uromodulin in kidney stone disease. The $368,500 award, effective September 1, 2024 through August 31, 2025, will support research to identify how defects in uromodulin polymerization and peptide excretion impact renal...
This Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA Program 93.350 provides funding of $437,761 to the University of Texas at Austin for a 2-year research project from August 2024 to July 2026. The project aims to determine if a human enzyme therapeutic that degrades cystine can prevent or slow the formation of cystine kidney stones and mitigate associated kidney pathology in a mouse model of cystinuria, a rare metabolic disorder causing...